A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
Completed · Phase 2
Conditions studied: Advanced Multiple Myeloma
In brief
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.
Key facts
- Study ID
- NCT01989325
- Run by
- Pfizer
- People needed
- 77
- Starts
- 2013-11-01
- Expected to finish
- 2016-05-01
- Last updated by the study team
- 2020-09-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Genesis Cancer Center — Hot Springs, Arkansas, United States
- UCLA — Los Angeles, California, United States
- St. Joseph Heritage Healthcare — Santa Rosa, California, United States
- Florida Cancer Specialists — Fort Myers, Florida, United States
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois, United States
- Crescent City Research Consortium — Marrero, Louisiana, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Forrest General Cancer Center — Hattiesburg, Mississippi, United States
- Nebraska Cancer Specialists — Omaha, Nebraska, United States
- Memorial Sloan Kettering — New York, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- Oncology Hematology Care - Blue Ash — Cincinnati, Ohio, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Ohio State University — Columbus, Ohio, United States
- Knight Cancer Institute at Oregon Health & Science University — Portland, Oregon, United States
- Prairie Lakes Health Care System — Watertown, South Dakota, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Simmons Cancer Center - UT Southwestern Medical Center — Dallas, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- WVU - Mary Babb Randolph Cancer Center — Morgantown, West Virginia, United States
- Medical College of Wisconsin Cancer Center — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.